Top Markets
#1 ADO Protocol ADO Protocol +328.82%
#2 GoPlus Security GoPlus Security +57.25%
#3 Starpower Starpower +44.49%
#4 Tutorial Tutorial +34.66%
#5 Verus Coin Verus Coin +33.62%
#6 Nockchain Nockchain +31.92%
#7 Chainflip Chainflip +28.11%
#8 The Black Bull The Black Bull +25.66%
#9 GAIB AID GAIB AID +24.67%
#10 Casper Network Casper Network +16.94%
Coin of the day
ADO Protocol ADO Protocol
設定
言語
日本
通貨
USD
テーマ
NuCana plc NuCana plc

NuCana plc

NCNA
株式のランク #32773
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
株価
$1.51
時価総額
$9.14M
変化（1日）
-5.35%
変化（1年）
-59.65%
国
GB
取引 NuCana plc (NCNA)

カテゴリー

Healthcare
NuCana plc（NCNA）のEPS
2026 時点のEPS TTM: 0
NuCana plcの最新の財務報告と株価によると、同社の現在のEPS（TTM）は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
NuCana plcのEPS履歴（2026から2026まで）
各年末時点のEPS
年 EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS
企業 EPS EPSの差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE